Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02242669 |
Recruitment Status :
Completed
First Posted : September 17, 2014
Last Update Posted : August 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Depression Bipolar Disorders Mood Disorders |
Study Type : | Observational |
Actual Enrollment : | 371 participants |
Observational Model: | Case-Control |
Time Perspective: | Other |
Official Title: | Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders |
Study Start Date : | November 2014 |
Actual Primary Completion Date : | April 2017 |
Actual Study Completion Date : | April 2017 |

Group/Cohort |
---|
AIM 1
200 current DBSA participants.
|
AIM 2
60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
|
AIM 3
100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
|
- Systematically gather empirical estimates of the characteristics of current DBSA participants through a cross-sectional survey of demographics, clinical service, and past and current DBSA attendance, involvement, and subjective benefits. [ Time Frame: Up to 24 months ]The goal is to describe and characterize DBSA participants and obtain information on subjective benefits.
- Provide estimates of rates of attendance, retention in, and discontinuation from DBSA for new DBSA members with mood disorders. [ Time Frame: Up to 24 months ]Determine which DBSA participants are more likely to attend more frequently/become more engaged.
- Conduct a prospective between-group investigation comparing new DBSA members to a matched control group with no prior exposure to DBSA in order to test for beneficial affects of DBSA over a 6-month follow up. [ Time Frame: Up to 24 months ]Compare new DBSA members to a matched control group in order to test for any potential incremental beneficial effects from DBSA participation.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Aim 1:
- 18 years of age or older
- Self-report a diagnosis of any type of mood disorder
- Attend DBSA meetings
- Aim 2:
- 18 years of age or older
- Self-report a diagnosis of any type of mood disorder
- Have attended their first meeting in the past month
- Aim 3:
- 18 years of age or older
- Self-report a diagnosis of any type of mood disorder
- Have never attended a DBSA meeting
Exclusion Criteria:
- Aim 1:
- Do not report a diagnosis of any type of mood disorder
- Have not attended a DBSA meeting
- Aim 2:
- Do not report a diagnosis of any type of mood disorder
- Have not attended a DBSA meeting
- Have attended their first meeting prior to a month before their assessment
- Aim 3:
- Do not report a diagnosis of any type of mood disorder
- Have attended a DBSA meeting

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02242669
United States, Massachusetts | |
McLean Hospital | |
Belmont, Massachusetts, United States, 02478 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | John F Kelly, PhD | Massachusetts General Hospital |
Responsible Party: | John F. Kelly, Associate Professor of Psychiatry Harvard Medical School, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT02242669 |
Other Study ID Numbers: |
2014P000153 R21MH101271-02 ( U.S. NIH Grant/Contract ) |
First Posted: | September 17, 2014 Key Record Dates |
Last Update Posted: | August 29, 2017 |
Last Verified: | August 2017 |
Disease Bipolar Disorder Mood Disorders |
Pathologic Processes Bipolar and Related Disorders Mental Disorders |